Observational studyOncotarget2016
The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters.
Observational study in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 5 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Association between Drug Therapy and Risk of Incident Frailty: A Systematic Review.Annals of geriatric medicine and research · 2024Pooled it
- Blood-based biomarkers of frailty in solid tumors: a systematic review.Frontiers in public health · 2023Pooled it
- Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review.European journal of cancer (Oxford, England : 1990) · 2022Pooled it
- The prevalence of frailty among breast cancer patients: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Pooled it
- The Effect of Cancer Treatments on Telomere Length: A Systematic Review of the Literature.Journal of the National Cancer Institute · 2018Pooled it
- Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Immune-inflammatory and nutritional status mediate the association between age and survival in older patients with nasopharyngeal carcinoma: a retrospective cohort study.BMC geriatrics · 2026Article
- An unfavorable biologic profile associated with decreased overall survival and cancer-specific survival in non-metastatic breast cancer: A latent class analysis.Translational oncology · 2026Article
- Molecular markers, mechanisms and metrics of biological aging: a scoping review.Frontiers in aging · 2026Review
- The 19th St. Gallen international breast cancer conference 'primary therapy of patients with early breast cancer. Evidence, controversies, consensus': key moments and breakthroughs.Ecancermedicalscience · 2026Article
- Development and validation of a risk prediction model for postoperative frailty in breast cancer patients.PeerJ · 2026Article
- Age-related and postmenopausal breast cancer progression and treatment management: The significance of pro-inflammatory cytokines and CXC chemokines.Genes & diseases · 2025Review
- Biological Aging and Chemotoxicity in Patients with Colorectal Cancer: A Secondary Data Analysis Using EHR Data.Current oncology (Toronto, Ont.) · 2025Article
- Accelerated Aging in Cancer and Cancer Treatment: Current Status of Biomarkers.Cancer medicine · 2025Review
- Development and validation of a prediction model for frailty in breast cancer patients with extended survival.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- A nomogram for predicting breast cancer specific survival in elderly patients with breast cancer: a SEER population-based analysis.BMC geriatrics · 2023Article
- 'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer.Journal of geriatric oncology · 2023Article
- Adjuvant Treatment of Elderly Breast Cancer Patients: Offer the Best Chances of Cure.Breast care (Basel, Switzerland) · 2022Review
- Breast Cancer in Geriatric Patients: Current Landscape and Future Prospects.Clinical interventions in aging · 2022Review
- Monitoring of telomere dynamics in peripheral blood leukocytes in relation to colorectal cancer patients' outcomes.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis prospective observational study aimed to evaluate the impact of adjuvant chemotherapy on biological and clinical markers of aging and frailty.
methodsWomen ≥ 70 years old with early breast cancer were enrolled after surgery and assigned to a chemotherapy (Docetaxel and Cyclophosphamide) group (CTG, n=57) or control group (CG, n=52) depending on their planned adjuvant treatment. Full geriatric assessment (GA) and Quality of Life (QoL) were evaluated at inclusion (T0), after 3 months (T1) and at 1 year (T2). Blood samples were collected to measure leukocyte telomere length (LTL), levels of interleukin-6 (IL-6) and other circulating markers potentially informative for aging and frailty: Interleukin-10 (IL-10), Tumor Necrosis Factor Alpha (TNF-α), Insulin-like Growth Factor 1 (IGF-1), Monocyte Chemotactic Protein 1 (MCP-1) and Regulated on Activation, Normal T cell Expressed and Secreted (RANTES).
resultsLTL decreased significantly but comparably in both groups, whereas IL-6 was unchanged at T2. However, IL-10, TNF-α, IGF-1 and MCP-1 suggested a minor biological aging effect of chemotherapy. Clinical frailty and QoL decreased at T1 in the CTG, but recovered at T2, while remaining stable in the CG.
conclusionsChemotherapy (TC) is unlikely to amplify clinical aging or induce frailty at 1 year. Accordingly, there is no impact on the most established aging biomarkers (LTL, IL-6).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.